|
|
News Breaks
|
November 14, 2011
|
| 08:58 EDT |  | THLD |
| theflyonthewall.com: | Threshold Pharma TH302 poised to provide catalyst, says JMP Securities | | JMP Securities expects data from Threshold's TH-302 to provide a major catalyst for the stock before the end of the year, and the firm expects the treatment to drive interest from investors and potential partners in 2012. The firm thinks the Street is likely overloooking the drug's potential and it reiterates an Outperform rating on Threshold. :theflyonthewall.com |
|
|
News For THLD From The Last 14 Days Check below for free stories on THLD the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 25, 2012
|
| 07:36 EDT | | THLD |
| theflyonthewall.com: | Threshold Pharmaceuticals remains undervalued, says Cowen | | Cowen said Threshold Pharmaceuticals remains undervalued in relation the potential of it's TH-302 drug for pancreatic cancer. The firm noted positive Phasellb results and estimates the sales potential in the U.S. alone at $1.5B+. Shares are Outperform rated. :theflyonthewall.com |
|
|
|
|
|
